These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 22653949)
1. FCA: forget chemoimmunotherapy with alemtuzumab? Hallek M Blood; 2012 May; 119(22):5059-60. PubMed ID: 22653949 [No Abstract] [Full Text] [Related]
2. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. Geisler CH; van T' Veer MB; Jurlander J; Walewski J; Tjønnfjord G; Itälä Remes M; Kimby E; Kozak T; Polliack A; Wu KL; Wittebol S; Abrahamse-Testroote MC; Doorduijn J; Ghidey Alemayehu W; van Oers MH Blood; 2014 May; 123(21):3255-62. PubMed ID: 24735962 [TBL] [Abstract][Full Text] [Related]
3. Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia. Mozas P; Rivas-Delgado A; Baumann T; Villamor N; Ortiz-Maldonado V; Aymerich M; Costa D; Navarro A; Giné E; López-Guillermo A; Montserrat E; Delgado J Blood Cancer J; 2018 Jan; 8(1):10. PubMed ID: 29339727 [No Abstract] [Full Text] [Related]
4. All is not lost--the improving outcome of patients with chronic lymphocytic leukaemia failing frontline therapy with fludarabine, cyclophosphamide and rituximab. Cheah CY; Lew TE; Lee R; Tam CS; Seymour JF; Carney DA Eur J Haematol; 2013 Aug; 91(2):189-90. PubMed ID: 23668259 [No Abstract] [Full Text] [Related]
6. Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study. Winqvist M; Palma M; Heimersson K; Mellstedt H; Österborg A; Lundin J Br J Haematol; 2018 Aug; 182(4):590-594. PubMed ID: 28677818 [No Abstract] [Full Text] [Related]
7. Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia. Feugier P; Aurran T; Mahé B; Letestu R; Nguyen-Khac F; Cazin B; Tournilhac O; Maisonneuve H; Casasnovas O; Delmer A; Leblond V; Royer B; Corront B; Chevret S; Delépine R; Vaudaux S; Van Den Neste E; Béné MC; Cymbalista F; Ross-Weil D; Leprêtre S Haematologica; 2018 Jul; 103(7):e304-e306. PubMed ID: 29545348 [No Abstract] [Full Text] [Related]
8. miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. Guinn D; Ruppert AS; Maddocks K; Jaglowski S; Gordon A; Lin TS; Larson R; Marcucci G; Hertlein E; Woyach J; Johnson AJ; Byrd JC Leukemia; 2015 May; 29(5):1210-3. PubMed ID: 25486872 [No Abstract] [Full Text] [Related]
9. The Shifting Paradigm in Chronic Lymphocytic Leukemia: Is Chemotherapy Still Relevant? Jain N; OʼBrien S Cancer J; 2019; 25(6):374-377. PubMed ID: 31764117 [TBL] [Abstract][Full Text] [Related]
10. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Chemoimmunotherapy should be standard frontline therapy. Wendtner CM Clin Adv Hematol Oncol; 2016 May; 14(5):336-8. PubMed ID: 27379694 [No Abstract] [Full Text] [Related]
11. Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG). Cramer P; Isfort S; Bahlo J; Stilgenbauer S; Döhner H; Bergmann M; Stauch M; Kneba M; Lange E; Langerbeins P; Pflug N; Kovacs G; Goede V; Fink AM; Elter T; Fischer K; Wendtner CM; Hallek M; Eichhorst B Haematologica; 2015 Nov; 100(11):1451-9. PubMed ID: 26315931 [TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. Al-Sawaf O; Fischer K; Herling CD; Ritgen M; Böttcher S; Bahlo J; Elter T; Stilgenbauer S; Eichhorst BF; Busch R; Elberskirch U; Abenhardt W; Kneba M; Hallek M; Wendtner CM Eur J Haematol; 2017 Mar; 98(3):254-262. PubMed ID: 27862308 [TBL] [Abstract][Full Text] [Related]
13. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study. Zent CS; Bowen DA; Conte MJ; LaPlant BR; Call TG Leuk Lymphoma; 2016 Jul; 57(7):1585-91. PubMed ID: 26699397 [TBL] [Abstract][Full Text] [Related]